cps 2

Drug Profile

cps 2

Alternative Names: rA2cp248/404-1030 Delta SH genetically stabilised; Recombinant live-attenuated respiratory syncytial virus vaccine - Medimmune/NIAID; Respiratory syncytial virus vaccine cps2; RSV vaccine live-attenuated genetically stabilised - Medimmune/NIAID

Latest Information Update: 25 Oct 2013

Price : $50

At a glance

  • Originator National Institute of Allergy and Infectious Diseases
  • Class Attenuated vaccines; Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Respiratory syncytial virus infections

Most Recent Events

  • 01 Sep 2013 Phase-I clinical trials in Respiratory syncytial virus infections (prevention in infants) in USA (Intranasal)
  • 01 Sep 2013 National Institute of Allergy and Infectious Diseases initiates enrolment in a phase I trial for Respiratory syncytial virus infections (prevention) in USA (NCT01968083)
  • 01 Jan 2012 Preclinical trials in Respiratory syncytial virus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top